National Property Portfolio on Auction

National Property Portfolio on Auction
Loading

‘Cancer drug price dropped’

June 20 2012 at 10:11am
By SAPA

Comment on this story

Pharma

REUTERS

A pharmacist counts pills in a pharmacy.

The department of health has persuaded pharmaceutical company Roche to halve the price of one of its cancer drugs, Business Day reported on Wednesday.

The department's deputy director general for regulation Anban Pillay said the drug rituximab, dubbed MabThera by Roche, had previously been too expensive for the state to buy and distribute to patients.

With the price halved, provinces with the capacity to offer cancer treatment will buy the drug, within the constraints of their budgets.

The department’s two-year tender for the drug, shows that government is willing to pay R7950 for a 50ml vial of the injectable rituximab, and R1590 for a 10ml vial.

Rituximab belongs to a class of medicines called biologics, and is used for treating non-Hodgkin’s lymphoma, leukaemia, and severe rheumatoid arthritis.

Roche is a price-setter for MabThera, as the only market with a rival product is India.

Pillay said the department was also in discussion with Roche over a “more affordable” price for its breast cancer drug Herceptin. - Sapa


sign up
 
 

Comment Guidelines


  1. Please read our comment guidelines.
  2. Login and register, if you haven’ t already.
  3. Write your comment in the block below and click (Post As)
  4. Has a comment offended you? Hover your mouse over the comment and wait until a small triangle appears on the right-hand side. Click triangle () and select "Flag as inappropriate". Our moderators will take action if need be.

     

Join us on

 IOL-Social networks IOL-Social networks IOL-Social networks IOL-Social networks
IOL Travel

Make sure you find the best available airfares with our easy-to-use search engine.

Travel_pic_enw
Sudoku